TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.57M | 11.21M | 9.17M | 8.26M | 7.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.57M | 11.21M | 9.17M | 8.26M | 7.35M |
| Cost of Revenue | 1.91M | 1.80M | 1.50M | 1.22M | 1.00M |
| Gross Profit | 9.66M | 9.41M | 7.67M | 7.05M | 6.35M |
| SG&A Expenses | 13.50M | 12.82M | 11.71M | 13.41M | 10.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.58M | 18.55M | 16.50M | 17.58M | 16.09M |
| Operating Income | -9.01M | -7.33M | -7.33M | -9.32M | -8.74M |
| Income Before Tax | -10.81M | -8.29M | -10.37M | -10.11M | -2.40M |
| Income Tax Expenses | 5.00K | -3.00K | 5.00K | -1.00K | -3.00K |
| Earnings from Continuing Operations | -10.81M | -8.29M | -10.38M | -10.11M | -2.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.81M | -8.29M | -10.38M | -10.11M | -2.40M |
| EBIT | -9.01M | -7.33M | -7.33M | -9.32M | -8.74M |
| EBITDA | -8.85M | -7.17M | -7.16M | -9.13M | -8.56M |
| EPS Basic | -0.96 | -0.23 | -0.39 | -0.40 | -0.12 |
| Normalized Basic EPS | -0.19 | -0.17 | -0.21 | -0.25 | -0.11 |
| EPS Diluted | -0.96 | -0.23 | -0.39 | -0.40 | -0.12 |
| Normalized Diluted EPS | -0.19 | -0.17 | -0.21 | -0.25 | -0.11 |
| Average Basic Shares Outstanding | 43.06M | 32.99M | 28.53M | 27.55M | 26.50M |
| Average Diluted Shares Outstanding | 43.06M | 32.99M | 28.53M | 27.55M | 26.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |